You are here: Industry Insights > Rozlytrek

News List

SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland pharmatimes
March 10, 2021
The Scottish Medicines Consortium (SMC) has accepted Novartis Gene Therapies' Zolgensma and Genentech’s Rozlytrek for use by NHS Scotland as part of its March 2021 decisions.
SMC kicks of the new year by accepting five new medicines for NHS use pharmatimes
January 20, 2021
Five newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC) following its first meeting of 2021.
Rozlytrek from Roche gets EC approval to treat solid tumours and NSCLC expresspharma
August 04, 2020
The approval is based on results from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials, and data from the phase I/II STARTRK-NG study.
NICE recommends Rozlytrek (entrectinib) as treatment for NSCLC europeanpharmaceuticalreview
June 17, 2020
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
NICE backs Rozlytrek for subset of NSCLC patients pharmatimes
June 16, 2020
NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment option for ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Rozlytrek Approved to Treat Tumors With NTRK Gene Fusion drugs
August 20, 2019
Rozlytrek (entrectinib), a kinase inhibitor, has received approval to treat adults and adolescents with cancer that carries the genetic defect neurotrophic tyrosine receptor kinase (NTRK) gene fusion and...
FDA grants Rozlytrek cancer treatment approval drugs
August 19, 2019
The cancer therapeutic, Rozlytrek, has gained FDA approval as well as Priority Review, Breakthrough Therapy and Orphan Drug Designations.
FDA Grants Accelerated Approval to Rozlytrek americanpharmaceuticalreview
August 19, 2019
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect ...
Roche scores Rozlytrek OK to challenge Bayer—and undercuts it on price fiercepharma
August 18, 2019
Roche’s targeted cancer drug Rozlytrek is officially cleared for U.S. launch—and in not one, but two indications.
Roche gets approval for oncology drug, Rozlytrek biospectrumasia
August 18, 2019
FDA Approves Genentech’s Personalized Medicine for Two Different Indications in ROS1-Positive Non-Small Cell Lung Cancer and NTRK Fusion-Positive Solid Tumors

Previous page 1 2 Next page